Apabetalone

DRUG6 trials

Conditions

COVID-19 InfectionCoronary Artery DiseaseDiabetes Mellitus, Type 2Kidney Failure, ChronicPost-Acute COVID-19 SyndromePulmonary Arterial Hypertension

Early Phase 1

Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study

CompletedNCT03655704

Steeve ProvencherPulmonary Arterial Hypertension

Start: 2019-08-22End: 2021-12-13Updated: 2022-04-25

Phase 1

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Not yet recruitingNCT03160430

Resverlogix CorpKidney Failure, Chronic

Start: 2024-11-22End: 2026-11-22Target: 44Updated: 2023-11-15

Phase 2

An Open-Label Study of Apabetalone in Covid Infection

TerminatedNCT04894266

Resverlogix CorpCOVID-19 Infection

Start: 2022-01-14End: 2022-06-22Updated: 2023-11-18

Apabetalone for Pulmonary Arterial Hypertension

NCT04915300

Laval UniversityPulmonary Arterial Hypertension

Start: 2023-10-31End: 2025-03-31Target: 72Updated: 2023-04-18

A Study of Apabetalone in Subjects With Long -COVID

RecruitingNCT06590324

Resverlogix CorpPost-Acute COVID-19 Syndrome

Start: 2025-04-15End: 2026-03-30Target: 200Updated: 2025-04-18

Phase 3

Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

CompletedNCT02586155

Resverlogix CorpCoronary Artery Disease, Diabetes Mellitus, Type 2

Start: 2015-11-30End: 2021-06-21Updated: 2021-08-20

Related Papers

#2999 APABETALONE REDUCES CARDIAC EVENTS IN CKD PATIENTS BY DOWNREGULATING FIBROTIC AND INFLAMMATORY PROCESSES

Nephrology Dialysis Transplantation2023-06-01

Apabetalone, a BET inhibitor, attenuates inflammation induced by viral RNA mimetic and reduces SARS-CoV-2 spike protein binding regardless of variants

European Heart Journal2022-10-01

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.

2021-06-2218 citations

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes

JAMA2020-03-27158 citations

Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease.

2020-01-0120 citations

How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?

2019-04-0117 citations